BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12042660)

  • 1. Graft-versus-host disease in the absence of the spleen after allogeneic bone marrow transplantation.
    Clouthier SG; Ferrara JL; Teshima T
    Transplantation; 2002 May; 73(10):1679-81. PubMed ID: 12042660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.
    Yang YG; Dey BR; Sergio JJ; Pearson DA; Sykes M
    J Clin Invest; 1998 Dec; 102(12):2126-35. PubMed ID: 9854048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
    Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
    Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model.
    Yang YG; Dey B; Sergio JJ; Sykes M
    Transplantation; 1997 Nov; 64(9):1343-52. PubMed ID: 9371678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
    Marks L; Altman NH; Podack ER; Levy RB
    Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
    Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
    Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR
    J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.
    Waller EK; Ship AM; Mittelstaedt S; Murray TW; Carter R; Kakhniashvili I; Lonial S; Holden JT; Boyer MW
    Blood; 1999 Nov; 94(9):3222-33. PubMed ID: 10556211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
    Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
    Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
    van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
    J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation.
    Cooke KR; Krenger W; Hill G; Martin TR; Kobzik L; Brewer J; Simmons R; Crawford JM; van den Brink MR; Ferrara JL
    Blood; 1998 Oct; 92(7):2571-80. PubMed ID: 9746799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
    Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
    Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
    J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation.
    Silva IA; Olkiewicz K; Askew D; Fisher JM; Chaudhary MN; Vannella KM; Deurloo DT; Choi SW; Pierce EM; Clouthier SG; Liu C; Cooke KR
    Biol Blood Marrow Transplant; 2010 May; 16(5):598-611. PubMed ID: 20117226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.